The FAAP20 antibody is a critical research tool for studying the Fanconi anemia-associated protein 20 (FAAP20), a key component of the Fanconi anemia (FA) pathway. This pathway is essential for repairing interstrand crosslinks (ICLs) and maintaining genomic stability. The antibody facilitates the detection and characterization of FAAP20 in cellular assays, immunoprecipitation, and chromatin localization studies.
FAAP20 is a 20-kDa protein containing a conserved ubiquitin-binding zinc-finger (UBZ) domain at its C-terminus, which binds K-63–linked ubiquitin chains in vitro . This domain is critical for its role in DNA damage response pathways, including recruitment to ICL sites and stabilization of the FA core complex .
The antibody is used in:
Immunoprecipitation (IP): To isolate FAAP20 and associated proteins (e.g., FANCA, FANCG) from nuclear lysates .
Immunoblotting (IB): To validate FAAP20 expression levels and interactions in wild-type vs. FA-deficient cells .
Chromatin Immunoprecipitation (ChIP): To map FAAP20 recruitment to ICL sites, with enrichment observed at cross-linked DNA substrates .
FAAP20 functions in:
FA Core Complex Integrity: Stabilizes FANCA and facilitates chromatin loading of FANCA/FANCG subcomplexes .
ICL Repair: Recruits to ICL sites via its UBZ domain, promoting FANCD2 monoubiquitination .
Homologous Recombination (HR): Supports RAD51 focus formation and single-strand annealing (SSA), with FANCA-dependent and -independent roles .
FANCA Dependency: FAAP20 stability is FANCA-dependent; knockdown of FANCA reduces FAAP20 levels via proteasomal degradation .
Cancer Prognosis: Overexpression correlates with unfavorable outcomes in liver cancer and favorable outcomes in pancreatic cancer .
Therapeutic Sensitivity: FAAP20-deficient cells show increased sensitivity to ionizing radiation and PARP inhibitors .
FAAP20 interacts with: